A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
暂无分享,去创建一个
M. Congreve | P. Maruff | P. Nathan | M. Weir | G. Light | D. Cross | O. Dewit | G. Bakker | T. Tasker | A. Godwood | J. Liptrot | B. Ruparelia | Stephen P. Jones | Alastair Brown | S. B. Millais